Save time and get answers to complex questions with AI chat
When will generic fiasap insulin be available?Is allopurinol expensive?Diltiazem drug class?Does lipitor's effectiveness decrease with high fat meals?Pramlintide approval date?
See the DrugPatentWatch profile for Rasagiline
How is rasagiline classified in the BCS? Rasagiline falls into Biopharmaceutics Classification System (BCS) Class I, meaning it is highly soluble and highly permeable when taken orally. [1] What does a Class I designation mean for rasagiline’s absorption? High solubility and permeability together predict good oral bioavailability; the drug is expected to dissolve quickly in gastrointestinal fluids and cross epithelial membranes efficiently. [1][2] Why does rasagiline’s solubility qualify it as high solubility? At 25 °C, rasagiline hydrochloride dissolves at concentrations above 1 mg mL⁻¹ in buffers at pH 1.2, 4.5, and 6.8, surpassing the 1‑mg mL⁻¹ threshold set for high solubility in the BCS. [1] How does its permeability compare to the BCS threshold? In vitro Caco‑2 permeability studies show a permeability coefficient (P_app) exceeding 10⁻⁶ cm s⁻¹, comfortably above the 10⁻⁶ cm s⁻¹ cut‑off used to define high permeability. [3] Does this classification simplify its oral formulation? Yes. Class I drugs usually do not need solubility‑enhancing excipients; standard tablet or capsule forms can achieve the required dissolution and absorption profiles. [2] What regulatory guidance applies to Class I drugs? Regulatory agencies, such as the FDA and EMA, allow biowaivers for in vitro dissolution studies for BCS Class I drugs, provided that the formulation demonstrates consistent dissolution under specified conditions. [2] Are there formulation patents specific to rasagiline? The original formulation patents focus on dosage strength and tablet compression rather than solubility or permeability enhancers, reflecting the drug’s Class I status. [1] Can rasagiline be delivered through non‑oral routes? Because of its high permeability, alternative routes such as transdermal or sublingual are theoretically possible, but no commercial products currently exploit these pathways. [3] What would happen if rasagiline’s permeability were lower? If permeability dropped below the BCS threshold, formulation strategies would shift toward permeability enhancers or delivery systems like nanoparticles to maintain therapeutic levels. [2] Sources [1] DrugBank: Rasagiline (DB01057) – BCS Class I. [2] WHO: Biopharmaceutics Classification System (BCS) table – Class I drugs. [3] Pharmacology & Therapeutics review on rasagiline pharmacokinetics.
Other Questions About Rasagiline :